Trial Profile

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Rituximab (Primary)
Indications Membranous glomerulonephritis
Focus Therapeutic Use
Acronyms REBOOT
Sponsors GSK

Most Recent Events

06 Nov 2024 Planned number of patients changed from 124 to 58.
06 Nov 2024 Status changed from active, no longer recruiting to recruiting.
18 Dec 2023 Planned End Date changed from 1 Oct 2026 to 1 Mar 2030.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com